The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

Not Applicable

Completed

• Conditions: Essential Hypertension
• Interventions: Other: Placebo; Drug: Spironolactone; Drug: Amiloride

• Registration Number: NCT01195805
• Lead Sponsor: Regional Hospital Holstebro

Brief Summary

The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.

Detailed Description

Purpose of the study is to examine the effect of amiloride and spironolactone on

1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK),

2. Pulsewave velocity, augmentation index central bloodpressure,

3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and

4. Ambulatory bloodpressure

Study Timeline

• Study Start: 2010-08
• Study First Submitted: 2010-09-03
• Study First Submitted QC: 2010-09-03
• Study First Posted: 2010-09-06
• Status Verified: 2013-03
• Primary Completion: 2015-08
• Study Completion: 2015-08
• Last Update Submitted: 2015-08-19
• Last Update Posted: 2015-08-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• hypertension,
• BMI 18,5-30,
• non-smoker

Exclusion Criteria

• Smoking
• Not using contraceptives
• Other illnesses
• Drug or alcohol abuse

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	1 tablet twice a day for 28 days
Spironolactone	Spironolactone	-
Amiloride	Amiloride	-

Primary Outcome Measures

Name	Time	Method
Bloodpressure	24-hours and examination

Trial Locations

Locations (1)

Departments of medical research and medicine; 🇩🇰 Holstebro, Denmark